Review Article

The role of JAK inhibitors in treating inflammatory diseases: From rheumatoid arthritis to beyond: Examining the use of Janus kinase inhibitors in managing autoimmune and inflammatory conditions

Deepak Kumar Bhateja

Department of Pharmacology, Physic Herbals, Panchkula, Haryana, India

Correspondence:
Dr. Deepak Kumar Bhateja, Physic Herbals, 226 Ram Nagar Kalka, Panchkula - 133 302, Haryana, India.
E-mail: bhatejadeepak@gmail.com

How to cite this article: Bhateja DK. The role of JAK inhibitors in treating inflammatory diseases: From rheumatoid arthritis to beyond. Examining the use of Janus kinase inhibitors in managing autoimmune and inflammatory conditions. Innov Pharm Planet (IP-Planet) 2024;12(2):24-27.

Source of Support: Nil.
Conflicts of Interest: None declared.

Date of Submission: 09-04-2024
Date of Revision: 17-04-2024
Date of Acceptance: 20-05-2024

ABSTRACT

Janus kinase (JAK) inhibitors have emerged as a promising therapeutic option for the management of various inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis, psoriatic arthritis, inflammatory bowel disease, and atopic dermatitis. These inhibitors target the JAK-signal transducers and activators of the transcription signaling pathway, modulating immune responses and offering an alternative to traditional therapies, such as biologics and disease-modifying antirheumatic drugs. JAK inhibitors are available in oral formulations, allowing for improved patient compliance and rapid onset of action. Despite their efficacy in controlling disease activity and enhancing patient quality of life, safety concerns, including risks of infections and thromboembolic events, remain significant. This review examines the mechanism of action, clinical applications, efficacy, safety profile, and future potential of JAK inhibitors in treating autoimmune and inflammatory diseases. The promising outlook for JAK inhibitors, including emerging therapies and combination strategies, underscores the need for ongoing research to refine their role in clinical practice.

Keywords: Atopic dermatitis, autoimmune diseases, clinical trials, drug efficacy, drug safety, immunomodulation, inflammatory bowel disease, inflammatory diseases, Janus kinase inhibitors, Janus kinase-signal transducers and activators of transcription pathway, psoriasis, psoriatic arthritis, rheumatoid arthritis, targeted therapy

Introduction

Inflammatory and autoimmune diseases represent a significant burden on health-care systems globally, affecting millions of individuals. Traditional therapeutic approaches, including non-steroidal anti-inflammatory drugs and biologics, have limitations in efficacy and safety profiles. As a result, there is a pressing need for novel therapeutic strategies that can provide effective relief while minimizing adverse effects. Janus kinase (JAK) inhibitors have emerged as a promising class of medications that target the underlying mechanisms of these diseases.

Access this article online

Website: https://innovationaljournals.com/index.php/ip | e-ISSN: 2348-7275

DOI: 10.31690/ipplanet.2024.v012i02.007

Overview of Inflammatory and Autoimmune Diseases

Inflammatory diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and inflammatory bowel disease (IBD), involve dysregulated immune responses characterized by excessive inflammation. Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues, leading to chronic inflammation and tissue damage. The JAK-signal transducers and activators of the transcription (STAT) signaling pathway plays a crucial role in mediating the effects of various pro-inflammatory cytokines involved in these conditions.[1]

JAK inhibitors target this pathway, providing a mechanism to modulate immune responses effectively. They have been shown to suppress intracellular signaling mediated by multiple cytokines, which is particularly beneficial in managing RA and other inflammatory diseases.[2]

The Need for Novel Therapeutic Approaches

Despite advancements in treatment options, many patients do not achieve adequate control of their symptoms with existing therapies. Conventional disease-modifying antirheumatic drugs (DMARDs) and biologics can be ineffective or associated with significant side effects.[3,4] This highlights the necessity for innovative therapies that can address unmet clinical needs.

JAK Inhibitors offer Several Advantages Over Traditional Therapies

Oral administration

Unlike many biologics that require injections, JAK inhibitors are available in oral formulations, enhancing patient compliance.

Rapid onset of action

These medications can provide quicker relief from symptoms compared to some conventional therapies.

Targeted mechanism

By selectively inhibiting specific JAK pathways, these drugs can minimize off-target effects and improve safety profiles.[5]

Efficacy and Safety of JAK Inhibitors

Several JAK inhibitors have received regulatory approval for various inflammatory conditions

Tofacitinib

Approved for RA, ulcerative colitis, and other conditions, tofacitinib has demonstrated significant efficacy in clinical trials, showing superior results compared to placebo in inducing remission.[1]

Baricitinib

This selective JAK1 and JAK2 inhibitor has also shown promise in treating RA and is being investigated for other autoimmune conditions.[4]

Upadacitinib

A JAK1-selective inhibitor approved for both RA and IBD, upadacitinib has been noted for its rapid action and favorable safety profile.[2]

Clinical studies have consistently shown that these agents not only improve disease activity scores but also enhance patients' quality of life. However, safety concerns remain, particularly regarding increased risks of infections and thromboembolic events associated with JAK inhibitor therapy.[6]

Understanding JAK Inhibitors

Mechanism of action of JAK inhibitors

JAK inhibitors are a class of medications that modulate the immune system by inhibiting the activity of one or more JAK enzymes, which are crucial for the JAK-STAT signaling pathway. This pathway transmits signals from various cytokines that play a significant role in inflammation and immune responses. When cytokines bind to their respective receptors, JAKs are activated and phosphorylate STATs, leading to gene activation involved in inflammatory processes.[7]

By blocking this signaling cascade, JAK inhibitors effectively suppress the actions of pro-inflammatory cytokines, which can help alleviate symptoms associated with autoimmune diseases such as RA.[8] The inhibition occurs through competitive bidding to the adenosine 5'-triphosphate-binding site of the JAK enzymes, preventing their activation and subsequent signaling.[7]

Types of JAK inhibitors: Selective versus non-selective

JAK inhibitors can be classified into selective and non-selective types based on their target specificity.

Selective JAK inhibitors

These agents preferentially inhibit specific JAK isoforms. For example:

Tofacitinib

Primarily inhibits JAK1 and JAK3, affecting cytokines such as interleukin (IL)-2 and IL-6.

Upadacitinib

A selective JAK1 inhibitor with a strong effect on IL-6 signaling.

Baricitinib

Targets both JAK1 and JAK2, impacting multiple inflammatory pathways.

Non-selective JAK inhibitors

These agents inhibit multiple JAK isoforms, potentially leading to broader effects on cytokine signaling. An example is peficitinib, which acts on all four JAKs (JAK1, JAK2, JAK3, and TYK2) and can modulate various inflammatory responses.[3]

Clinical applications in RA

JAK inhibitors have been increasingly utilized in the treatment of RA due to their efficacy in controlling disease activity. They represent a new class of targeted synthetic DMARDs, offering an alternative for patients who do not respond adequately to traditional therapies.

Efficacy of JAK inhibitors in RA treatment

Clinical trials have demonstrated that JAK inhibitors significantly improve symptoms and reduce disease activity in RA patients. For instance, studies such as ORAL SYNC and SELECT NEXT have shown that tofacitinib and upadacitinib provide rapid relief from symptoms and improve physical function compared to placebo.[9] The efficacy is attributed to their ability to inhibit multiple inflammatory pathways simultaneously, making them effective even in patients with inadequate responses to conventional DMARDs.

Comparison with traditional disease-modifying drugs

Unlike traditional DMARDs that often target single pathways or specific cytokines (such as tumor necrosis factor inhibitors), JAK inhibitors offer a broader mechanism of action by interfering with multiple cytokine signals involved in inflammation. This multitarget approach allows for more comprehensive management of RA symptoms.[10]

Traditional DMARDs can take weeks to months to exhibit effects, whereas JAK inhibitors typically show a quicker onset of action, often within days.[8] However, while they provide significant benefits, there are considerations regarding safety profiles, including risks of infections and other adverse effects associated with systemic immunosuppression.

JAK Inhibitors in Other Autoimmune Diseases

Psoriasis and PsA

JAK inhibitors have been increasingly recognized as effective treatment options for psoriasis and PsA. Tofacitinib and upadacitinib are among the approved JAK inhibitors for PsA, whereas deucravacitinib has been introduced for psoriasis. These agents target the JAK-STAT signaling pathway, which is crucial in the inflammatory processes underlying these conditions. Clinical trials have demonstrated significant efficacy in improving symptoms, with studies reporting high rates of achieving a 75% improvement in the psoriasis area and severity index 75.[11]

IBD

In addition to dermatological applications, JAK inhibitors are also being explored for IBD, including ulcerative colitis and Crohn's disease. Tofacitinib has received approval for ulcerative colitis, showing substantial efficacy in inducing and maintaining remission. The mechanism of action remains consistent, targeting the JAK pathway to inhibit pro-inflammatory cytokine signaling, thereby reducing inflammation in the gastrointestinal tract.[12]

Atopic dermatitis (AD)

AD is another area where JAK inhibitors are being investigated. Preliminary studies suggest that these agents can effectively reduce the severity of AD by modulating immune responses associated with this chronic skin condition. The inhibition of JAK enzymes helps to decrease the activity of cytokines involved in the inflammatory response, providing relief from symptoms such as itching and skin lesions.

Safety and Side Effects

Common and severe adverse effects

While JAK inhibitors offer promising benefits, they are associated with several potential side effects. Common adverse effects include:

- Nausea
- Headaches
- Increased cholesterol levels
- Diarrhea
- Upper respiratory infections.

More severe risks may include

- Serious infections
- Abnormal blood counts
- Liver function abnormalities
- Gastrointestinal perforations

Long-term use raises concerns about chronic immunosuppression, necessitating careful monitoring of patients.[13,14]

Long-term safety considerations

The long-term safety profile of JAK inhibitors is still under investigation. While short-term studies indicate that these medications are generally well-tolerated, ongoing research is essential to evaluate their effects over extended periods. Monitoring for serious adverse events, especially infections and malignancies, is crucial as these therapies continue to be integrated into treatment regimens for chronic inflammatory diseases.[15]

Advances in JAK Inhibitor Therapy

Emerging JAK inhibitors in clinical trials

Numerous new JAK inhibitors are currently undergoing clinical trials, expanding the therapeutic landscape for autoimmune diseases. Drugs targeting specific isoforms such as TYK2 show promise in treating conditions such as psoriasis and IBD, potentially offering improved efficacy and safety profiles compared to existing options.[12]

Personalized medicine and biomarkers for JAK inhibitor therapy

The future of JAK inhibitor therapy may involve personalized approaches based on biomarkers that predict response to treatment. Identifying specific patient characteristics or genetic markers could help tailor therapies more effectively, enhancing outcomes while minimizing risks.[11]

Future Perspectives and Challenges

Expanding the scope of JAK inhibitors beyond autoimmunity

Research is ongoing into the potential applications of JAK inhibitors beyond autoimmune diseases, including their role in treating certain cancers and other inflammatory conditions. This expansion could significantly impact how physicians' approach various chronic diseases.

Potential for combination therapies

Combining JAK inhibitors with other therapeutic modalities, such as biologics or conventional DMARDs, may enhance treatment efficacy

while mitigating side effects. This strategy could be particularly beneficial for patients with complex disease profiles who do not respond adequately to monotherapy.

Ongoing research and clinical developments

Continuous research efforts aim to refine the understanding of JAK inhibitors' mechanisms and optimize their use across different patient populations. Ongoing clinical trials will provide valuable data on long-term safety, efficacy, and potential new indications for these therapies.[10]

Conclusion

JAK inhibitors mark a significant advancement in treating inflammatory and autoimmune diseases, offering targeted therapy with improved symptom control and fewer risks compared to traditional treatments. Their effectiveness in RA, psoriasis, PsA, IBD, and AD highlights their potential across various conditions. However, safety concerns, particularly regarding infections and long-term use, require careful monitoring. Ongoing research will refine their safety profiles and expand their applications, making JAK inhibitors an essential part of future treatment strategies for chronic inflammatory diseases.

Summary of benefits and limitations of JAK inhibitors

Benefits

- Rapid onset of action
- Oral administration for better compliance
- Effective for multiple autoimmune conditions.

Limitations

- Risk of serious infections
- Uncertainty about long-term safety
- Potentially high costs

The outlook for JAK inhibitors remains promising, but continued research is necessary to ensure their safety and efficacy.

References

1. Tanaka Y, Luo Y, O'Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach. Nat Rev Rheumatol 2022;18:133-45.
2. Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Sève P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev 2019;18:102390.
3. Taylor PC, Choy E, Baraliakos X, Szekanecz Z, Xavier R, Isaacs JD, *et al*. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases. Rheumatology 2024;63:298-308.
4. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 2017;16:843-62.
5. Honap S, Agorogianni A, Colwill MJ, Mehta SK, Donovan F, Pollok R, *et al*. JAK inhibitors for inflammatory bowel disease: Recent advances. Frontline Gastroenterol 2024;15:59-69.
6. McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet 2021;398:803-16.
7. O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013;72 Suppl 2, ii111-5.
8. Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A Comprehensive overview of globally approved JAK inhibitors. Pharmaceutics 2022;14:1001.
9. Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, *et al*. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: A consensus statement. Ann Rheum Dis 2021;80:71-87.
10. Boyadzhieva Z, Ruffer N, Burmester G, Pankow A, Krusche M. Effectiveness and safety of JAK inhibitors in autoinflammatory diseases: A systematic review. Front Med 2022;9:930071.
11. Megna M, Potestio L, Ruggiero A, Cacciapuoti S, Maione F, Tasso M, *et al*. JAK inhibitors in psoriatic disease. Clin Cosmet Investig Dermatol 2023;3129-3145.
12. Sarabia S, Ranjith B, Koppikar S, Wijeratne DT. Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: A systematic review and meta-analysis. BMC Rheumatol 2022;6:71.
13. Kvist-Hansen A, Hansen PR, Skov L. Systemic treatment of psoriasis with JAK inhibitors: A review. Dermatol Ther (Heidelb) 2020;10:29-42.
14. Campanaro F, Batticciotto A, Zaffaroni A, Cappelli A, Donadini MP, Squizzato A. JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis. Autoimmun Rev 2021;20:102902.
15. Raychaudhuri S, Shah RJ, Raychaudhuri SK, Raychaudhuri SP. Janus kinase inhibitors for the treatment of psoriatic arthritis. Indian J Dermatol Venereol Leprol 2024;90:186-91.